In the FLAURA trial, osimertinib led to superior PFS and longer OS compared to other EGFR‐TKIs (erlotinib or gefitinib) in untreated EGFR‐mutated advanced NSCLC patients [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.